Baxalta now part of Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Baxalta now part of Shire sits in the top decile of US sponsors by registered trial count (#294 of 15,742 sponsors by registered trial count).
Baxalta now part of Shire: 74 sponsored US clinical trials, 1 recruiting.
Baxalta now part of Shire sponsors 74 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 58 completed. 34 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemophilia A, with 4 trials.
Top-decile sponsor footprint
Baxalta now part of Shire ranks in the top decile of sponsors by registered trial count (#294 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 71 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
74 total, page 2 of 2
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
NCT00818662
Gammagard Liquid and rHuPH20 in PID
NCT00814320
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
NCT00816660
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
NCT00666263
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
NCT00952822
A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly
NCT00333528
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
NCT00546871
Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously
NCT00333515
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
NCT00782106
Aralast alpha1-proteinase Inhibitor Surveillance Study
NCT00313144
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
NCT00357656
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00289536
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386
Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
NCT00161720
ADVATE Post Authorization Safety Surveillance
NCT00214734
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
NCT00157157
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
NCT00157092
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
NCT00157118
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
NCT00161707
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
NCT00157079
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
NCT00157040
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157053
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
NCT00157105
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
NCT00003056
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 11 |
| Phase 3 | 29 |
| Phase 4 | 5 |
What is open in the Baxalta now part of Shire pipeline
1 recruiting of 74 indexed (1% open); 58 completed (78%).
Phase mix: 34 late (III/IV) vs 26 early (I/II) (balanced across stages).
Top condition: Hemophilia A (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baxalta now part of Shire: open-pipeline peers nationwide
Peers matched on 74 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Baxalta now part of Shire sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 74 trials (± recruiting share)
- C. R. Bard · 75 trials · 5% recruiting
- ECOG-ACRIN Cancer Research Group · 75 trials · 16% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Astellas Pharma · 1% recruiting · 165 trials
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Baxalta now part of Shire page
74 registered trials is a research-attention snapshot, not an endorsement of Baxalta now part of Shire or any single study.
- 1 of Baxalta now part of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hemophilia A is the condition Baxalta now part of Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hemophilia A trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Baxalta now part of Shire pipeline card: 74 registered trials from official public datasets.Report a data error.